← Back to headlines
Novartis Acquires Allergy-Drug Developer Excellergy for Up to $2 Billion
Pharmaceutical company Novartis is expanding its allergy medication business with the acquisition of the unlisted US biotech firm Excellergy in a deal valued at up to $2 billion, marking its second multi-billion dollar acquisition in a week and betting on a next-generation allergy treatment.
27 Mar, 11:43 — 27 Mar, 12:33
The Story
Analyzing sources…
Source Diversity
Source Diversity
High (56/100)4 sources30/33
Spectrum spread— 3/5 buckets covered17/33
Far L
Left1
Left (1)
cnbc
Center1
Center (1)
bloomberg
Right2
Right (2)
wsjdie-presse
Far R
Geographic diversity— 2 regions9/34
US3Austria1
Sources
Showing 2 of 4 sources
wsjHigh1d ago
Novartis to Buy Allergy-Drug Developer Excellergy for Up to $2 Billion - WSJ
Novartis to Buy Allergy-Drug Developer Excellergy for Up to $2 Billion WSJ
Read full article →cnbcMostly Factual1d ago
Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week
The Swiss pharma giant is betting on a next-generation allergy treatment that may prove to work faster and better than anything currently on the market.
Read full article →Coverage Timeline
First report: die-presse · 27 Mar, 07:00|Full coverage: 4 · 6h|Window: 6h
Left-leaningCenterRight-leaning
Related Stories
Philippine Lawmaker Urges Government to Build Coastal Petroleum Storage Facilities
just now
DICT Pledges Wider Free Internet Access on Philippines' 32nd Connectivity Anniversary
just now
Philippine SSS Considers Loan Relief and Condonation Programs
just now
Bank of America to Pay $72.5 Million Settlement in Epstein Lawsuit
12m ago